Media
Press releases
15Nov
Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA
12Nov
Hansa Biopharma Nomination Committee formed
08Nov
Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO
Media assets
Executive Leadership Team
Dr Christian Kjellman
Senior Vice President, Chief Scientific Officer, Research and Development
